Literature DB >> 8623620

Nonspecificity of short inversion time inversion recovery (STIR) as a technique of fat suppression: pitfalls in image interpretation.

G Krinsky1, N M Rofsky, J C Weinreb.   

Abstract

Short inversion time inversion recovery (STIR) and the rapid acquisition with relaxation enhancement (RARE) version of STIR are commonly used pulse sequences that are sensitive enough to detect a broad range of pathologic conditions. In addition to suppressing the signal from fat, the STIR sequence achieves additive T1-weighted, T2-weighted, and proton density-weighted contrast to facilitate lesion conspicuity [1, 2]. Fat suppression with STIR sequences is based on short T1 relaxation rates and therefore is not tissue specific. The signal from any tissue with a short T1, similar to that of fat, may be nulled as well. The signal from tissues that accumulate paramagnetic contrast agents also may be suppressed with STIR sequences when an appropriate degree of T1 shortening results.

Mesh:

Substances:

Year:  1996        PMID: 8623620     DOI: 10.2214/ajr.166.3.8623620

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  17 in total

1.  Post-processing water-fat imaging technique for fat suppression in a low-field MR imaging system, evaluation in patients with rheumatoid arthritis.

Authors:  Kari Palosaari; Osmo Tervonen
Journal:  MAGMA       Date:  2002-11       Impact factor: 2.310

2.  Contrast-enhanced MR myelography in spontaneous intracranial hypotension: description of an artefact imitating CSF leakage.

Authors:  Elke Hattingen; Richard DuMesnil; Ulrich Pilatus; Andreas Raabe; Timo Kahles; Jürgen Beck
Journal:  Eur Radiol       Date:  2009-02-24       Impact factor: 5.315

Review 3.  Musculoskeletal imaging at 3 T: imaging and optimization.

Authors:  James S Meyer
Journal:  Pediatr Radiol       Date:  2008-05

Review 4.  Added value of diffusion-weighted acquisitions in MRI of the abdomen and pelvis.

Authors:  William A Moore; Gaurav Khatri; Ananth J Madhuranthakam; Robert D Sims; Ivan Pedrosa
Journal:  AJR Am J Roentgenol       Date:  2014-05       Impact factor: 3.959

5.  Combine contrast-enhanced 3D T2-weighted short inversion time inversion recovery MR neurography with MR angiography at 1.5 T in the assessment of brachial plexopathy.

Authors:  Zhengdao Xu; Tonghua Zhang; Jianxin Chen; Zongbao Liu; Tao Wang; Yijiang Hu; Jiahui Zhang; Feifei Xue
Journal:  MAGMA       Date:  2020-07-13       Impact factor: 2.310

6.  Use of chemical shift encoded magnetic resonance imaging (CSE-MRI) for high resolution fat-suppressed imaging of the brachial and lumbosacral plexuses.

Authors:  Allison Grayev; Scott Reeder; Amgad Hanna
Journal:  Eur J Radiol       Date:  2016-04-11       Impact factor: 3.528

7.  Altered signal intensity of active enhancing inflammatory lesions using post-contrast double inversion recovery MR sequence.

Authors:  Jérôme Hodel; Sammy Badr; Olivier Outteryck; Paul Lebert; David Chechin; Mohamed Amine Benadjaoud; Jean-Pierre Pruvo; Patrick Vermersch; Xavier Leclerc
Journal:  Eur Radiol       Date:  2016-05-27       Impact factor: 5.315

Review 8.  Fat-suppression techniques for 3-T MR imaging of the musculoskeletal system.

Authors:  Filippo Del Grande; Francesco Santini; Daniel A Herzka; Michael R Aro; Cooper W Dean; Garry E Gold; John A Carrino
Journal:  Radiographics       Date:  2014 Jan-Feb       Impact factor: 5.333

9.  Comparing the diagnostic utility of sacroiliac spectral CT and MRI in axial spondyloarthritis.

Authors:  Ping Zhang; Kai Hu Yu; Rui Min Guo; Jun Ran; Yao Liu; John Morelli; Val A Runge; Xiao Ming Li
Journal:  Br J Radiol       Date:  2015-12-16       Impact factor: 3.039

10.  Improved fat suppression using multipeak reconstruction for IDEAL chemical shift fat-water separation: application with fast spin echo imaging.

Authors:  Richard Kijowski; Michael A Woods; Kenneth S Lee; Kuya Takimi; Huanzhou Yu; Ann Shimakawa; Jean H Brittain; Scott B Reeder
Journal:  J Magn Reson Imaging       Date:  2009-02       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.